Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Nicotine Addiction - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H2 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape. Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT). Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively. Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Nicotine Addiction - Overview Nicotine Addiction - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Nicotine Addiction - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Nicotine Addiction - Companies Involved in Therapeutics Development Addex Therapeutics Ltd C4X Discovery Holdings PLC Chronos Therapeutics Ltd CV Sciences Inc Hager Biosciences LLC Heptares Therapeutics Ltd Omeros Corp Nicotine Addiction - Drug Profiles (cannabidiol + nicotine bitartrate) - Drug Profile Product Description Mechanism Of Action R&D Progress 18-MC - Drug Profile Product Description Mechanism Of Action R&D Progress ADX-71441 - Drug Profile Product Description Mechanism Of Action R&D Progress AT-1001 - Drug Profile Product Description Mechanism Of Action R&D Progress CTDP-002 - Drug Profile Product Description Mechanism Of Action R&D Progress EORA-101 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies for Nicotine Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Noribogaine - Drug Profile Product Description Mechanism Of Action R&D Progress OMS-405 - Drug Profile Product Description Mechanism Of Action R&D Progress OMS-527 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Nicotine Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress URB-694 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Nicotine Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Nicotine Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Nicotine Addiction - Drug Profile Product Description Mechanism Of Action R&D Progress Nicotine Addiction - Dormant Projects Nicotine Addiction - Discontinued Products Nicotine Addiction - Product Development Milestones Featured News & Press Releases Jul 20, 2017: CV Sciences Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure Jul 11, 2017: CV Sciences Appoints Dr. Amy M. McCord as Director of Drug Development Jun 19, 2017: CV Sciences Announces Commencement of IND preparation immediately following Pre-IND Meeting With FDA May 02, 2017: CV Sciences Announces Pre-IND Meeting Date with FDA May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Nicotine Addiction, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H2 2017 Nicotine Addiction - Pipeline by C4X Discovery Holdings PLC, H2 2017 Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H2 2017 Nicotine Addiction - Pipeline by CV Sciences Inc, H2 2017 Nicotine Addiction - Pipeline by Hager Biosciences LLC, H2 2017 Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd, H2 2017 Nicotine Addiction - Pipeline by Omeros Corp, H2 2017 Nicotine Addiction - Dormant Projects, H2 2017 Nicotine Addiction - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
